All In Biotech

Drug Trial Radar · NCT07321951

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

201

Actual

Start

Jan 9, 2026

Primary completion

Jun 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

Conditions

  • Moderate-to-severe Atopic Dermatitis

Interventions

  • SHR-1819 InjectionDrug

    SHR-1819 injection.

  • SHR-1819 Injection Blank PreparationDrug

    SHR-1819 injection blank preparation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants who achieved EASI-75 (≥75% decrease in the score on the Eczema Area and Severity Index (EASI) from the baseline).Time frame: Week 24.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.